1. Home
  2. QURE vs IVA Comparison

QURE vs IVA Comparison

Compare QURE & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo uniQure N.V.

QURE

uniQure N.V.

HOLD

Current Price

$47.51

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo Inventiva S.A. American Depository Shares

IVA

Inventiva S.A. American Depository Shares

HOLD

Current Price

$3.41

Market Cap

883.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QURE
IVA
Founded
1998
2011
Country
Netherlands
France
Employees
248
77
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
883.8M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
QURE
IVA
Price
$47.51
$3.41
Analyst Decision
Buy
Strong Buy
Analyst Count
14
10
Target Price
$45.00
$16.20
AVG Volume (30 Days)
2.6M
1.1M
Earning Date
05-05-2026
03-30-2026
Dividend Yield
N/A
N/A
EPS Growth
29.67
N/A
EPS
N/A
N/A
Revenue
$13,107,000.00
N/A
Revenue This Year
$126.12
N/A
Revenue Next Year
$200.43
$751.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.73
$2.94
52 Week High
$71.50
$7.98

Technical Indicators

Market Signals
Indicator
QURE
IVA
Relative Strength Index (RSI) 73.18 30.98
Support Level $21.63 N/A
Resistance Level $60.70 $4.67
Average True Range (ATR) 2.85 0.18
MACD 1.76 0.01
Stochastic Oscillator 87.87 10.27

Price Performance

Historical Comparison
QURE
IVA

About QURE uniQure N.V.

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.

Share on Social Networks: